Novel Antischizophrenia Treatments

Häftad, Engelska, 2014

Del 213 i serien Handbook of Experimental Pharmacology

4 476 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Produktinformation

Utgivningsdatum:2014-11-09
Mått:155 x 235 x 26 mm
Vikt:703 g
Format:Häftad
Språk:Engelska
Serie:Handbook of Experimental Pharmacology
Antal sidor:458
Förlag:Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN:9783642438097

Utforska kategorier

Biologisk psykologi och neuropsykologi inom Psykologi och pedagogik
Psykiatri inom Medicin
Farmakologi inom Medicin

Recensioner i media

From the reviews: "The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

Innehållsförteckning

Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.